Showing 151-160 of 332 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Single-arm intervention trial of TWIIST™ AID DEKA Loop insulin pump in pregnant women with pre-existing type 1 diabetes | Stanford University | Tugce Akcan | Improving Lives | 01-March-2025 to 28-February-2027 | $180,600.00 |
| Novel insulin formulations for pumps | Stanford University | Yanxian Zhang | Improving Lives | 01-March-2023 to 28-February-2026 | $243,986.00 |
| Achieving Health in Emerging Adults with Diabetes Program | Seattle Childrens Hospital | Faisal Malik | Improving Lives | 01-September-2024 to 31-August-2028 | $1,734,029.00 |
| PREdictors for DiabetIC Ketoacidosis at Diagnosis of Type 1 Diabetes (The PREDICT study) | Rutgers, The State University of New Jersey | Chintan Dave | Cures | 01-August-2022 to 31-July-2025 | $695,404.04 |
| The master regulator transcription factor, Zbtb20, defines and controls a regulatory T cell subset that controls tissue inflammation. | Rutgers Biomedical and Health Sciences | Derek Sant’Angelo | Cures | 01-March-2023 to 28-February-2026 | $935,026.00 |
| Treating Type 1 Diabetes: Role of Kisspeptin | Rutgers Biomedical and Health Sciences | Moshmi Bhattacharya | Cures | 01-April-2024 to 31-March-2026 | $140,000.00 |
| JDRF Cures Patient Preference Study in Type 1 Diabetes | RTI International | Carol Mansfield | Transportfolio | 01-July-2023 to 23-August-2025 | $756,300.00 |
| Using Genome Sequencing and Genetic Risk Scores to Identify Newborns with Serious Health Conditions: A Statewide Implementation Study | RTI International | Curt Scharfe | Cures | 01-December-2022 to 30-November-2025 | $3,356,049.93 |
| Effects of Volagidemab on Glucagon Rescue from Insulin-Induced Hypoglycemia | REMD Biotherapeutics | Dung Thai | Improving Lives | 30-June-2023 to 29-June-2026 | $672,000.00 |
| Hybrid Closed Loop Therapy for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study (CLVerEX) | Regents of the University of Minnesota | Antoinette Moran | Cures | 01-April-2023 to 31-March-2026 | $1,739,442.00 |